X4 Pharmaceuticals (XFOR) Operating Expenses (2017 - 2025)

X4 Pharmaceuticals has reported Operating Expenses for 9 years, with the latest figure at -$7.7 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 121.02% year-over-year to -$7.7 million; the trailing twelve-month figure through Dec 2025 stood at -$8.4 million (down 109.1% YoY), and the FY2025 full-year result was -$49.3 million, down 226.48% from the prior year.
• Operating Expenses for Q4 2025 stood at -$7.7 million, down from $28.9 million in the prior quarter.
• The five-year high for Operating Expenses was $37.3 million in Q1 2024, with the low at -$19.7 million in Q1 2025.
• Historically, Operating Expenses has averaged $18.2 million across 5 years, with a median of $23.2 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Expenses tumbled 158.38% — and 2025, when it surged 282.05%.
• X4 Pharmaceuticals' Operating Expenses stood at $29.1 million in 2021, then retreated by 11.97% to $25.6 million in 2022, then dropped by 1.48% to $25.2 million in 2023, then surged by 46.22% to $36.8 million in 2024, then slumped by 121.02% to -$7.7 million in 2025.
• The last three Operating Expenses figures came in at -$7.7 million (Q4 2025), $28.9 million (Q3 2025), and -$9.9 million (Q2 2025), per Business Quant data.